[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Sklifosovsky Institute of Emergency Care\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":193},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,49,78,113,145,173],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100643941","reliability-and-reproducibility-of-facet-joint-measurements-in-the-thoracolumbar-spine-100643941",false,"NCT07670039","Reliability and Reproducibility of Facet Joint Measurements in the Thoracolumbar Spine","Reliability and Reproducibility of Pathria Scale-Based Grading of Facet Joint Degeneration and Facet Joint Morphometric Measurements in the Thoracolumbar Spine","Inclusion Criteria:\n\n* availability of CT scans covering the T9-L3 vertebrae;\n* absence of imaging artifacts at the level of interest.\n\nExclusion Criteria:\n\n* bone mineral density of the vertebrae of \\\u003C100 HU;\n* systemic diseases of bone or joints associated with changes in the FJs and IvDs (including diffuse idiopathic skeletal hyperostosis, ankylosing spondylitis, rheumatoid arthritis, etc.);\n* previous spinal surgery, including procedures performed without instrumentation;\n* spinal fractures involving injury to the posterior structures;\n* participation in other clinical studies related to the treatment of spinal disorders or spinal trauma.","ALL","18 Years","65 Years",{"count":20,"type":21},12,"ESTIMATED","OBSERVATIONAL","The purpose is to determine how reliably degenerative changes in the facet joints (FJs) and intervertebral discs (IvDs) can be assessed on computed tomography (CT) scans.\n\nAt least six raters, including neurosurgeons and CT specialists, will independently evaluate anonymized CT scans covering the T9-L3 levels. The study will assess reproducibility of the Pathria grading scale for FJ degeneration and of quantitative measurements such as FJ space width and FJ angulation.",[25,26,27,28,29],"Facet Joint Arthritis","Facet Joints; Degeneration","Facet Joint Disease","Intervertebral Disk Degeneration","Pathria Classification",[31,32,33,34,35,36],"Thoracolumbar Spine","Facet Joint","Intervertebral Disc","Computed Tomography","interobserver reliability","intraobserver reliability","NOT_YET_RECRUITING","2026-06-27",{"date":40,"type":41},"2026-07-01","ACTUAL",{"date":40,"type":21},{"date":44,"type":21},"2026-11-01",{"name":46,"class":47},"Sklifosovsky Institute of Emergency Care","OTHER_GOV",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":16,"minAge":17,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":60,"conditions":61,"keywords":65,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":73,"startDateStruct":74,"completionDateStruct":75,"leadSponsor":77,"locationsCount":48},"100644645","degenerative-changes-after-treatment-of-thoracolumbar-junction-fractures-100644645","NCT07672184","Degenerative Changes After Treatment of Thoracolumbar Junction Fractures","Degenerative Changes in Injured and Adjacent Spinal Motion Segments After Conservative and Surgical Treatment of AOSpine Type A2, A3, and A4 Thoracolumbar Junction Fractures","Inclusion Criteria:\n\nConservative Treatment Cohort:\n\n* Age 18 to 50 years.\n* Acute or subacute traumatic fracture of the thoracolumbar junction at the start of treatment.\n* AOSpine type A2, A3, or A4 fracture.\n* No clinical evidence of nerve root or spinal cord compression at the injured level.\n* Conservative treatment of the thoracolumbar junction fracture.\n* Minimum follow-up period of 1 year.\n* Written informed consent for prospective follow-up or additional study procedures, when applicable.\n\nSurgical Treatment Cohort:\n\n* Age 18 to 50 years.\n* Acute or subacute traumatic fracture of the thoracolumbar junction at the start of treatment.\n* AOSpine type A2, A3, or A4 fracture.\n* No clinical evidence of nerve root or spinal cord compression at the injured level.\n* Surgical treatment performed without disruption of the posterior supporting column.\n* Surgical treatment may include anterior fusion, transpedicular fixation, or combined surgery without direct posterior decompression.\n* Minimum follow-up period of 1 year.\n* Written informed consent for prospective follow-up or additional study procedures, when applicable.\n\nControl Cohort:\n\n* Age 18 to 50 years.\n* At least two computed tomography examinations covering the Th9-L4 vertebral levels.\n* Interval of at least 1 year between computed tomography examinations.\n* Computed tomography performed for reasons unrelated to traumatic or degenerative thoracolumbar junction disease.\n* No imaging artifacts at the spinal levels included in the study assessment.\n\nExclusion Criteria:\n\nConservative Treatment Cohort:\n\n* Severe combined trauma.\n* Severe concomitant disease.\n* Systemic bone or joint disease associated with changes in facet joints or intervertebral discs, including diffuse idiopathic skeletal hyperostosis, ankylosing spondylitis, rheumatoid arthritis, or similar disorders.\n* Verified osteoporosis.\n* Bone density of thoracolumbar vertebrae less than 100 Hounsfield units.\n* Previous spine surgery.\n* American Society of Anesthesiologists physical status class 4 or 5.\n* Participation in another clinical study related to treatment of spinal disease or spinal trauma.\n* Withdrawal of informed consent, when applicable.\n\nSurgical Treatment Cohort:\n\n* Severe combined trauma.\n* Severe concomitant disease.\n* Systemic bone or joint disease associated with changes in facet joints or intervertebral discs, including diffuse idiopathic skeletal hyperostosis, ankylosing spondylitis, rheumatoid arthritis, or similar disorders.\n* Verified osteoporosis.\n* Bone density of thoracolumbar vertebrae less than 100 Hounsfield units.\n* Previous spine surgery.\n* Direct posterior decompression or other surgery disrupting the posterior supporting column.\n* American Society of Anesthesiologists physical status class 4 or 5.\n* Participation in another clinical study related to treatment of spinal disease or spinal trauma.\n* Withdrawal of informed consent, when applicable.\n\nControl Cohort:\n\n* Complicated fracture of any spinal region.\n* Combined trauma or severe concomitant disease limiting patient mobility.\n* Systemic bone or joint disease associated with changes in facet joints or intervertebral discs, including diffuse idiopathic skeletal hyperostosis, ankylosing spondylitis, rheumatoid arthritis, or similar disorders.\n* Grade 4 facet joint degeneration according to the Pathria classification at the studied levels.\n* Bone density of thoracolumbar vertebrae less than 100 Hounsfield units.\n* Previous spine surgery, including surgery without implants.\n* Spinal fracture with injury to the posterior supporting column.\n* Participation in another clinical study related to treatment of spinal disease or spinal trauma.",true,"50 Years",{"count":59,"type":21},150,"This observational study will evaluate how degenerative changes in the facet joints and intervertebral discs develop over time after treatment of AOSpine type A2, A3, and A4 fractures of the thoracolumbar junction. Patients treated conservatively and patients treated surgically will be compared with each other and with a control group of patients who underwent repeated computed tomography examinations for reasons unrelated to traumatic or degenerative spinal disease.\n\nThe study will assess computed tomography findings at the injured spinal motion segment and adjacent segments, including facet joint degeneration, intervertebral disc degeneration, signs of ankylosis, facet joint space parameters, and facet joint angle. Clinical outcomes in the fracture cohort will be evaluated using pain scores and validated questionnaires. The purpose of the study is to identify factors associated with progression of degenerative changes after thoracolumbar junction fractures and to clarify whether treatment method is associated with long-term degeneration of the injured and adjacent spinal motion segments.",[62,63,64],"Thoracolumbar Spine Fracture","Facet Joint Degeneration","Intervertebral Disc Degeneration",[66,67,68,69,70,63,64,71,72,34],"Thoracolumbar Junction Fracture","AOSpine Classification","AOSpine Type A2 Fracture","AOSpine Type A3 Fracture","AOSpine Type A4 Fracture","Adjacent Segment Degeneration","Spinal Motion Segment",{"date":40,"type":41},{"date":44,"type":21},{"date":76,"type":21},"2027-12-31",{"name":46,"class":47},{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":89,"phases":90,"briefSummary":92,"conditions":93,"keywords":97,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":112},"100460304","necessity-of-fusion-following-decompression-surgery-in-patients-with-single-level-lumbar-stenosis-100460304","NCT05273879","Necessity of Fusion Following Decompression Surgery in Patients With Single-level Lumbar Stenosis","Necessity of Fusion Following Decompression Surgery in Patients With Single-level Lumbar Stenosis: Study Protocol for an Open-label Multicenter Non-inferiority Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* age of patients from 45 to 75 years;\n* stenosis C or D according to Shizas et al. according to MRI at the level of L2-L3, L3-L4, L4-L5 or L5-S1;\n* clinical manifestations of lumbar stenosis (neurogenic claudication syndrome and\u002For radiculopathy);\n* lack of effect from conservative therapy within 3 months;\n* Informed consent to take part in the study.\n\nExclusion Criteria:\n\n* spondylolisthesis more than 3 mm;\n* spinal instability according to functional radiography;\n* sagittal imbalance (type 4 according to C. Barrey);\n* bone density of the vertebrae at the level of the operation is less than 100 HU;\n* clinically significant spinal stenosis at 2 or more levels;\n* previously performed surgeries on the spine;\n* risk of anesthesia 4 or 5 according to ASA;\n* inability to take part in control examinations within 2 years after the operation;\n* participation in other clinical trials related to surgical or conservative treatment of diseases of the spine.","45 Years","75 Years",{"count":88,"type":21},86,"INTERVENTIONAL",[91],"NA","Long-term clinical results of two methods of surgical treatment (spinal decompression with or without fusion) in patients with single-level lumbar stenosis will be compared. A clear framework for surgical treatment methods and standardized postoperative rehabilitation treatment will be set to obtain the maximum homogeneity of the patient groups.\n\nThis trial should provide the first level of evidence for the need for spinal fusion in patients with single-level lumbar stenosis, subject to the high homogeneous comparison groups. Additional results will allow comparing the economic aspects of different surgical treatments for 2 years after surgery.",[94,95,96],"Lumbar Spinal Stenosis","Spinal Stenosis","Spinal Fusion",[98,99,100,101,102],"lumbar spine","lumbar fusion","laminotomy","decompression without fusion","lumbar stenosis","RECRUITING","2025-12-11",{"date":106,"type":41},"2025-12-18",{"date":108,"type":41},"2022-04-01",{"date":110,"type":21},"2026-12-30",{"name":46,"class":47},2,{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":121,"enrollmentInfo":122,"targetDuration":4,"studyType":89,"phases":124,"briefSummary":125,"conditions":126,"keywords":129,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":48},"100475718","concurrent-fluorescence-and-sonographically-guided-eradication-of-contrast-enhancing-gliomas-and-metastases-100475718","NCT05474573","Concurrent Fluorescence and Sonographically Guided Eradication of Contrast-enhancing Gliomas and Metastases","Concurrent Fluorescence and Sonographically Guided Eradication of Gliomas and Metastases Enhancing Contrast Agent in Magnetic Resonance Imaging: a Randomised, Controlled Trial","CONFLUENSE","Inclusion Criteria:\n\n* single gliomas with contrast enhancement in preoperative magnetic resonance imaging (presumed high-grade gliomas)\n* one or several brain metastases from any cancer\n* newly diagnosed\n* Karnofsky Performance Status 60-100%\n* age 18-79 years\n* performed magnetic resonance imaging with contrast enhancement\n\nExclusion Criteria:\n\n* tumor spreading to corpus callosum or brainstem\n* previously performed brain radiotherapy\n* planned supratotal tumor resection until neurophysiologically revealed eloquent areas\n* known hypersensibility to 5-aminolevulinic or to porphyrin\n* hepatic or renal insufficiency\n* porphyria\n* pregnancy\n* breast feeding","79 Years",{"count":123,"type":21},52,[91],"Objective of the study is to determine whether combined use of intraoperative fluorescence with 5-aminolevulinic acid (5-ALA) and sonography can achieve higher rate of gross total resection of contrast-enhancing gliomas and brain metastases compared to intraoperative fluorescence with 5-ALA alone.",[127,128],"Glioma, Malignant","Metastases to Brain",[130,131,132,133,134,135,136],"contrast-enhancing glioma","brain metastasis","sonography","ultrasound","fluorescence","5-aminolevulinic acid","5-ALA","2025-05-13",{"date":139,"type":41},"2025-05-16",{"date":141,"type":41},"2022-09-01",{"date":143,"type":21},"2027-08-31",{"name":46,"class":47},{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":153,"enrollmentInfo":154,"targetDuration":4,"studyType":89,"phases":156,"briefSummary":157,"conditions":158,"keywords":163,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":169,"startDateStruct":170,"completionDateStruct":171,"leadSponsor":172,"locationsCount":48},"100475957","intraoperative-brain-shift-calculation-study-100475957","NCT05477680","Intraoperative Brain Shift Calculation Study","Intraoperative Brain Shift Calculation Study: a Prospective, Single Arm Clinical Trial","BRASH","Inclusion Criteria:\n\n* all intracranial tumors\n* cavernomas\n* arteriovenous malformations\n* spontaneous (non-traumatic) intracerebral hemorrhages\n* traumatic intracerebral hemorrhages\n* supratentorial localization\n* newly diagnosed\n* age 18-100 years\n* stable hemodynamics\n* error of patient registration in neuronavigation no more than 2 mm\n\nExclusion Criteria:\n\n* rapid cerebral dislocation","100 Years",{"count":155,"type":21},100,[91],"The purpose of the study is to calculate magnitude, type of intraoperative brain shift and assess possibility of it's prediction.",[159,160,161,162],"Tumor, Brain","Cavernoma","Arteriovenous Malformations","Intracerebral Hematoma",[164,165,166,167,168],"brain shift","tumor","cavernoma","arteriovenous malformation","intracerebral hematoma",{"date":139,"type":41},{"date":141,"type":41},{"date":143,"type":21},{"name":46,"class":47},{"id":174,"slug":175,"hasResults":11,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":179,"eligibilityCriteria":180,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":153,"enrollmentInfo":181,"targetDuration":4,"studyType":89,"phases":182,"briefSummary":183,"conditions":184,"keywords":185,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":189,"startDateStruct":190,"completionDateStruct":191,"leadSponsor":192,"locationsCount":48},"100476462","sonography-guided-resection-of-brain-mass-lesions-100476462","NCT05484245","Sonography-guided Resection of Brain Mass Lesions","Sonography-guided Resection of Brain Mass Lesions: a Prospective, Single Arm Clinical Trial","SOMALI","Inclusion Criteria:\n\n* all intracranial tumors\n* cavernomas\n* arteriovenous malformations\n* spontaneous (non-traumatic) intracerebral hemorrhages\n* traumatic intracerebral hemorrhages\n* supratentorial localization\n* newly diagnosed\n* age 18-100 years\n* stable hemodynamics\n\nExclusion Criteria:\n\n* rapid cerebral dislocation\n* previously performed brain radiotherapy",{"count":155,"type":21},[91],"Objective of the study is to determine possibilities of intraoperative sonography in detecting of various brain mass lesions, assessing extent of their resection and define indications to use ultrasound-guided needle or ultrasound wire-guided port.",[159,161,160,162],[186,187,188,166,167,168],"intraoperative sonography","intraoperative ultrasound","brain tumor",{"date":139,"type":41},{"date":141,"type":41},{"date":143,"type":21},{"name":46,"class":47},""]